Rapport Therapeutics (RAPP) Interest & Investment Income (2023 - 2026)

Rapport Therapeutics (RAPP) has 4 years of Interest & Investment Income data on file, last reported at $4.4 million in Q1 2026.

• On a quarterly basis, Interest & Investment Income rose 43.12% year-over-year to $4.4 million in Q1 2026; TTM through Mar 2026 was $14.9 million, a 11.68% increase from a year earlier, with the FY2025 full-year figure at $13.6 million, up 12.18% from the prior year.
• Interest & Investment Income for Q1 2026 stood at $4.4 million, down from $4.7 million in the prior quarter.
• Over the last five years, Interest & Investment Income for RAPP reached as high as $4.7 million in Q4 2025 and fell as low as $221000.0 in Q2 2023.
• Historically, Interest & Investment Income has averaged $2.7 million across 4 years, with a median of $2.9 million in 2025.
• Across the five-year window, Interest & Investment Income jumped 1112.22% in 2024 and slipped 25.4% in 2025, its largest moves.
• Year by year, Interest & Investment Income stood at $1.4 million in 2023, then jumped by 157.53% to $3.5 million in 2024, then jumped by 34.03% to $4.7 million in 2025, then decreased by 8.18% to $4.4 million in 2026.
• Per Business Quant data, the three most recent Interest & Investment Income figures were $4.4 million in Q1 2026, $4.7 million in Q4 2025, and $3.1 million in Q3 2025.